A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Launched by SICHUAN BAILI PHARMACEUTICAL CO., LTD. · May 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment combination called BL-B01D1 and PD-1 for patients with locally advanced or metastatic urothelial carcinoma, which is a type of bladder cancer that has spread or cannot be surgically removed. The goal of this phase II trial is to see how effective and safe this combination therapy is for people with this condition. The trial is currently looking for participants aged 18 to 75 who have not received any previous treatment for their advanced cancer and have a specific type of tumor confirmed by testing.

Participants in this study can expect to undergo regular monitoring and assessments while receiving the treatment. To be eligible, individuals must be in reasonably good health, with an expected survival time of at least three months and certain organ functions meeting the study's requirements. Additionally, women who can become pregnant will need to take precautions to prevent pregnancy during the trial. If you or someone you know has urothelial carcinoma and meets these criteria, this trial could be an opportunity to access potentially beneficial treatment while contributing to important research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. All subjects voluntarily participated in the study and signed informed consent;
• • 2. Male or female aged ≥18 years and ≤75 years;
• • 3. Expected survival time ≥3 months;
• • 4. ECOG 0-1;
• • 5. Unresectable locally advanced or metastatic urothelial carcinoma confirmed by histopathology and/or cytology;
• • 6. Participants should not have received previous systemic therapy for locally advanced or metastatic urothelial cancer;
• • 7. A biopsy sample of archived tumor tissue or metastatic urothelial carcinoma must be available within 3 years for PD-L1 and other testing;
• • 8. At least one measurable lesion meeting the RECIST v1.1 definition was required;
• • 9. The level of organ function must meet the requirements on the premise that blood transfusion and the use of any cell growth factors and/or platelet-raising drugs are not allowed within 14 days before the first dose;
• • 10. Previous treatment-related toxicity returned to ≤ grade 1 defined by NCI-CTCAE v5.0;
• • 11. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, the serum or urine pregnancy test must be negative, and the patient must not be lactating; All enrolled patients should take adequate barrier contraception during the entire treatment cycle and for 6 months after the end of treatment.
• Exclusion Criteria:
• • 1. Prior ADC recipients with TOPI inhibitors as toxin;
• • 2. Palliative radiotherapy within 2 weeks before the first dose;
• • 3. Prior immunotherapy with grade ≥3 irAE or grade ≥2 immune-related myocarditis;
• • 4. Use of an immunomodulatory drug within 14 days before the first dose of study drug;
• • 5. The history of severe cardiovascular and cerebrovascular diseases in the past six months was screened;
• • 6. QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;
• • 7. Active autoimmune and inflammatory diseases;
• • 8. Receiving \&gt before the first dose; Long-term systemic corticosteroid therapy with prednisone 10mg/d;
• • 9. Other malignant tumors that progressed or required treatment within 5 years before the first dose;
• • 10. Presence of: a) poorly controlled diabetes mellitus before starting study treatment; b) severe complications associated with diabetes mellitus; c) a glycated hemoglobin level of 8% or more; d) hypertension poorly controlled by two antihypertensive drugs; e) history of hypertensive crisis or hypertensive encephalopathy;
• • 11. History of ILD, current ILD, or suspected ILD;
• • 12. Complicated with pulmonary diseases leading to clinically severe respiratory impairment;
• • 13. Screening for unstable thrombotic events requiring therapeutic intervention within the preceding 6 months; Infusion-related thrombosis was excluded;
• • 14. Patients with active central nervous system metastases;
• • 15. Patients with massive or symptomatic effusions or poorly controlled effusions;
• • 16. Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or allergic to any excipients of the test drug;
• • 17. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT);
• • 18. HIV antibody positive, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
• • 19. Serious infection within 4 weeks before the first dose of study drug; Signs of pulmonary infection or active pulmonary inflammation within 4 weeks;
• • 20. Participated in another clinical trial within 4 weeks before the first dose;
• • 21. Patients with superior vena cava syndrome should not be rehydrated;
• • 22. Have a history of psychotropic substance abuse with an inability to quit or a history of severe neurological or psychiatric illness;
• • 23. Imaging examination showed that the tumor had invaded or wrapped the large thoracic vessels;
• • 24. Severe unhealed wound, ulcer, or fracture within 4 weeks before signing the informed consent;
• • 25. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;
• • 26. Subjects who are scheduled to receive live vaccine or receive live vaccine within 28 days before the first dose;
• • 27. Other circumstances considered by the investigator to be inappropriate for participation in the trial.